Pages that link to "Q39230910"
Jump to navigation
Jump to search
The following pages link to Randomised clinical trial: macrogol/PEG 3350 electrolytes versus prucalopride in the treatment of chronic constipation -- a comparison in a controlled environment (Q39230910):
Displaying 31 items.
- Patient considerations in the management of chronic constipation: focus on prucalopride (Q26741304) (← links)
- Recent Updates on the Treatment of Constipation (Q26820242) (← links)
- Disorders of gastrointestinal hypomotility (Q28070278) (← links)
- Comparison of the effectiveness of polyethylene glycol with and without electrolytes in constipation: a systematic review and network meta-analysis (Q28077823) (← links)
- Emerging Pharmacologic Therapies for Constipation-predominant Irritable Bowel Syndrome and Chronic Constipation (Q33586854) (← links)
- Understanding and treating refractory constipation (Q33621273) (← links)
- Effect of electroacupuncture versus prucalopride for severe chronic constipation: protocol of a multi-centre, non-inferiority, randomised controlled trial (Q33984572) (← links)
- Systematic review with meta-analysis: highly selective 5-HT4 agonists (prucalopride, velusetrag or naronapride) in chronic constipation (Q35059682) (← links)
- Resting anal pressure, not outlet obstruction or transit, predicts healthcare utilization in chronic constipation: a retrospective cohort analysis (Q36096138) (← links)
- Effective Constipation Treatment Changes More Than Bowel Frequency: A Systematic Review and Meta-Analysis (Q36426025) (← links)
- Pharmacological agents currently in clinical trials for disorders in neurogastroenterology (Q37200907) (← links)
- Linaclotide: new mechanisms and new promise for treatment in constipation and irritable bowel syndrome (Q37253910) (← links)
- Prucalopride: a review of its use in the management of chronic constipation (Q38160205) (← links)
- New pharmacological treatment options for chronic constipation. (Q38198743) (← links)
- Efficacy and safety of prucalopride in adults and children with chronic constipation (Q38300258) (← links)
- New Options in Constipation Management (Q38602701) (← links)
- Prucalopride: A Review in Chronic Idiopathic Constipation (Q38656212) (← links)
- New therapeutic perspectives in irritable bowel syndrome: Targeting low-grade inflammation, immuno-neuroendocrine axis, motility, secretion and beyond (Q42695148) (← links)
- Long-term outcome of prucalopride for chronic constipation: a single-centre study (Q43332981) (← links)
- DA-9701 improves colonic transit time and symptoms in patients with functional constipation: A prospective study (Q43361941) (← links)
- An update on prucalopride in the treatment of chronic constipation (Q45044943) (← links)
- Colorectal Transit and Volume During Treatment With Prolonged-release Oxycodone/Naloxone Versus Oxycodone Plus Macrogol 3350. (Q47141999) (← links)
- Risk of developing colorectal cancer and benign colorectal neoplasm in patients with chronic constipation (Q51139976) (← links)
- Chronic constipation. (Q52751094) (← links)
- Polyethylene glycol in constipation-predominant irritable bowel syndrome. (Q52840528) (← links)
- Recent advances in understanding and managing chronic constipation (Q58562464) (← links)
- Management of functional constipation in children and adults (Q91130406) (← links)
- Polyethylene glycol-based laxatives for chronic constipation (Q92586491) (← links)
- Polyethylene glycol-based laxatives for chronic constipation - Authors' reply (Q92586496) (← links)
- Clinical Efficacy and Safety Profile of Prucalopride in Chronic Idiopathic Constipation (Q92889328) (← links)
- Efficacy of drugs in chronic idiopathic constipation: a systematic review and network meta-analysis (Q93044822) (← links)